Valeant’s Bausch + Lomb Revenues Dip 3 percent in Q2-2017

August 11, 2017: By Jon Swedien

Valeant PharmaceuticalsValeant’s Pharmaceuticals’ Bausch + Lomb segment posted revenues of $1.24 billion in Q2-2017, a decrease of 3 percent (+1 percent, cc) compared with $1.28 billion for Q2-2016, the company reported Aug. 8.

In an earnings call, Valeant Chairman and CEO Joseph Papa said the Bausch + Lomb/International segment represented 56 percent of Valeant’s revenues in the quarter. He noted B+L’s strong performance in China (+4 percent, +9 percent cc), driven by volume.

Valeant posted total revenues of $2.23 billion in Q2-2017, an 8 percent decrease (-5 percent, cc) compared with Q2-2016.

The company said it remained committed to lowering its debt and had reduced the total by more than $4.8 billion since Q1-2016.

Its total long-term debt is currently $28.5 billion.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Eylea Gains Approval in China for DME-Related Visual Impairment

Second Trial for Ophthalmic Industry Leader James Mazzo Ends in Hung Jury, Mistrial

Melgen Receives 17-Year Sentence for Medicare Fraud

NIH’s National Eye Institute Solicits Next-Generation Retina Organoids in $1 Million Prize Competition

Taiwan Liposome Company Registers for $50 Million IPO in US

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023